Michelle OLaughlin
Overview
Explore the profile of Michelle OLaughlin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
3591
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jacoby M, Duncavage E, Khanna A, Chang G, Nonavinkere Srivatsan S, Miller C, et al.
Leukemia
. 2024 Oct;
39(1):166-177.
PMID: 39367170
Accurate assessment of therapy response in myelodysplastic neoplasm (MDS) has been challenging. Directly monitoring mutational disease burden may be useful, but is not currently included in MDS response criteria, and...
2.
Slade M, Ghasemi R, OLaughlin M, Burton T, Fulton R, Abel H, et al.
JCO Precis Oncol
. 2023 Apr;
7:e2200559.
PMID: 37079859
Purpose: Persistent molecular disease (PMD) after induction chemotherapy predicts relapse in AML. In this study, we used whole-exome sequencing (WES) and targeted error-corrected sequencing to assess the frequency and mutational...
3.
Ghobadi A, Miller C, Li T, OLaughlin M, Lee Y, Ali M, et al.
Haematologica
. 2019 Mar;
104(8):e373-e375.
PMID: 30923101
No abstract available.
4.
Christopher M, Petti A, Rettig M, Miller C, Chendamarai E, Duncavage E, et al.
N Engl J Med
. 2018 Nov;
379(24):2330-2341.
PMID: 30380364
Background: As consolidation therapy for acute myeloid leukemia (AML), allogeneic hematopoietic stem-cell transplantation provides a benefit in part by means of an immune-mediated graft-versus-leukemia effect. We hypothesized that the immune-mediated...
5.
Duncavage E, Jacoby M, Chang G, Miller C, Edwin N, Shao J, et al.
N Engl J Med
. 2018 Sep;
379(11):1028-1041.
PMID: 30207916
Background: Allogeneic hematopoietic stem-cell transplantation is the only curative treatment for patients with myelodysplastic syndrome (MDS). The molecular predictors of disease progression after transplantation are unclear. Methods: We sequenced bone...
6.
Jacoby M, Duncavage E, Chang G, Miller C, Shao J, Elliott K, et al.
JCI Insight
. 2018 Mar;
3(5).
PMID: 29515031
Allogeneic hematopoietic cell transplantation (alloHCT) is a potentially curative treatment for myelodysplastic syndromes (MDS), but patients who relapse after transplant have poor outcomes. In order to understand the contribution of...
7.
Spencer D, Russler-Germain D, Ketkar S, Helton N, Lamprecht T, Fulton R, et al.
Cell
. 2017 Feb;
168(5):801-816.e13.
PMID: 28215704
DNMT3A mutations occur in ∼25% of acute myeloid leukemia (AML) patients. The most common mutation, DNMT3A, has dominant negative activity that reduces DNA methylation activity by ∼80% in vitro. To...
8.
Duncavage E, Uy G, Petti A, Miller C, Lee Y, Tandon B, et al.
Blood
. 2017 Jan;
129(10):1397-1401.
PMID: 28082444
No abstract available.
9.
Shirai C, White B, Tripathi M, Tapia R, Ley J, Ndonwi M, et al.
Nat Commun
. 2017 Jan;
8:14060.
PMID: 28067246
Somatic mutations in spliceosome genes are detectable in ∼50% of patients with myelodysplastic syndromes (MDS). We hypothesize that cells harbouring spliceosome gene mutations have increased sensitivity to pharmacological perturbation of...
10.
Welch J, Petti A, Miller C, Fronick C, OLaughlin M, Fulton R, et al.
N Engl J Med
. 2016 Dec;
375(21):2023-2036.
PMID: 27959731
Background: The molecular determinants of clinical responses to decitabine therapy in patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) are unclear. Methods: We enrolled 84 adult patients with...